Plasma kicks off mainnet beta on September 25 backed by $2 billion in stablecoins and support from over 100 DeFi partners. The debut includes the XPL token, designed to secure the network and give ownership to the community. According to…Plasma kicks off mainnet beta on September 25 backed by $2 billion in stablecoins and support from over 100 DeFi partners. The debut includes the XPL token, designed to secure the network and give ownership to the community. According to…

Plasma eyes mainnet launch with $2b stablecoin liquidity and XPL token

Plasma kicks off mainnet beta on September 25 backed by $2 billion in stablecoins and support from over 100 DeFi partners. The debut includes the XPL token, designed to secure the network and give ownership to the community.

Summary
  • Plasma will launch its mainnet beta on Sept. 25 with $2 billion in stablecoin liquidity.
  • The rollout includes support from over 100 DeFi partners and the debut of the XPL token.
  • The launch positions Plasma among the top 10 blockchains by stablecoin value locked.

According to an announcement on September 18, the Plasma Foundation will activate its mainnet beta on September 25 at 8:00 AM ET alongside the token generation event for its native XPL token.

Notably, the rollout will include the migration of $2 billion in pre-committed stablecoin liquidity from Plasma’s vaults onto the new chain, a capital base that will instantly position it among the top 10 blockchains by stablecoin value locked.

From committed capital to real-world utility

Per the announcement, the $2 billion set to go live on Plasma’s mainnet beta will be deployed across more than 100 DeFi partners, including Aave, Ethena, Fluid and Euler to create immediate utility for users and establish deep Tether markets.

To complete its final launch phase, Plasma will bridge existing vault deposits onto the chain, enabling depositors to withdraw a native stable asset called USD₮0 and tying early vault commitments to on-chain liquidity.

Plasma will also activate zero-fee USDT transfers for all users through its dedicated dashboard. Initially, this fee waiver will be available for transfers within Plasma’s own products as the network undergoes initial stress testing, with plans to extend it to broader applications over time. This fee waiver is powered by PlasmaBFT, a custom consensus mechanism engineered specifically for high-throughput stablecoin settlement.

The XPL token forms the other half of the launch. Its tokenomics emphasize broad, aligned ownership. Ten percent of the total supply was allocated to the public sale. An additional 25 million XPL will be distributed at launch to smaller depositors who have completed KYC verification, while 2.5 million XPL is reserved for members of the Stablecoin Collective, rewarding their role in education and adoption.

XPL serves as the core for network security, aligning incentives for validators and ensuring those who use and build on Plasma share in its ownership. Distribution for non-U.S. participants begins at launch, while U.S. participants will receive their allocations in July 2026 in compliance with applicable regulations.

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Paylaş
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Paylaş
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Paylaş
BitcoinEthereumNews2025/09/18 05:26